Ferroptosis in ovarian cancer chemotherapy resistance: current perspectives and therapeutic implications
Cancer Advances · 2026 · 9 · e26010
DOI: 10.53388/2026926010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Advances, 2026. Verfasst von Sheng-Ye Hou und 10 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Ovarian cancer, the most fatal gynecological malignancy worldwide, continues to show a year-by-year increase in both incidence and mortality rates. Approximately 70% of patients are already diagnosed at an advanced stage due to the lack of obvious early symptoms and effective screening methods. Treatment resistance has become a major therapeutic hurdle in clinical practice, which directly leads to an extremely poor five-year overall survival rate in affected patients. Conventional platinum-based chemotherapy, as the first-line treatment, often loses its efficacy gradually with the continuous development of drug resistance, thus urgently necessitating the exploration and development of novel therapeutic strategies and targets. Ferroptosis, a unique regulated cell death pathway distinct from traditional apoptosis and necrosis, has attracted extensive research interest in recent years owing to its special molecular mechanism and biological characteristics. This review systematically elaborates and analyzes the key molecular mechanisms linking ferroptosis to chemotherapy resistance in ovarian cancer, and further discusses the potential clinical application value and therapeutic prospects of targeting ferroptosis. The purpose of this study is to provide new theoretical insights and feasible intervention strategies for reversing tumor chemoresistance and improving the prognosis of ovarian cancer patients.
Zitieren
APA
Hou, S., Lv, Y., Fan, J., Guo, Y., Wang, X., Liu, C., Zhai, X., Gong, T., Yu, B., Guo, R., & Li, X. (2026). Ferroptosis in ovarian cancer chemotherapy resistance: current perspectives and therapeutic implications. Cancer Advances, 9(0), e26010. https://doi.org/10.53388/2026926010
Vancouver
Hou S, Lv Y, Fan J, Guo Y, Wang X, Liu C, et al. Ferroptosis in ovarian cancer chemotherapy resistance: current perspectives and therapeutic implications. Cancer Advances. 2026;9(0):e26010. doi:10.53388/2026926010
BibTeX
@article{Hou2026,
author = {Hou, Sheng-Ye and Lv, Yun-Jiao and Fan, Jing-Jing and Guo, Yu-Meng and Wang, Xiao-Nan and Liu, Chen and Zhai, Xiang and Gong, Tao and Yu, Bao-Feng and Guo, Rui and Li, Xiao-Ning},
title = {Ferroptosis in ovarian cancer chemotherapy resistance: current perspectives and therapeutic implications},
journal = {Cancer Advances},
year = {2026},
volume = {9},
number = {0},
pages = {e26010},
doi = {10.53388/2026926010}
}
EUVIMED